Plain-English translation of NCT04319367 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination of two long-acting antibody medications called 3BNC117-LS and 10-1074-LS in people who started HIV treatment very early after infection and have kept the virus completely controlled for at least a year. The goal is to see whether these antibodies can keep the virus suppressed if someone stops taking their daily antiretroviral pills.
Current HIV treatment requires taking pills every day for life. This medication aims to offer an alternative: antibodies that work for months at a time, which could give people more freedom and flexibility in how they manage their HIV.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the experimental antibody medication (or placebo) at the study center, then you will be asked to stop taking your daily HIV pills while doctors closely monitor your blood work and viral load very frequently. If your viral load starts to rise, you will restart your daily medication. Depending on which group you're in, you may be eligible for a second round of antibody infusions and monitoring. The study continues until your virus is controlled again or the study team decides to restart your regular medication.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Denmark
United Kingdom